Costs vs. Outcomes for Patients With Type 2 Diabetes: The issue of cost in healthcare is a central point in the discussion of the future of medicine. While much is made of the cost of end-of-life care, many of the dollars spent yearly are focused on the treatment of chronic diseases like diabetes. The estimated yearly cost of diabetes care was $245 billion in the U.S. in 2012, the last year for which numbers have been reported. $50 billion of that was related to prescription drug purchases.

Part 1 of a series on a framework developed by Dr. Bradley Eilerman and Len Testa for recommending medications for treating patients with type 2 diabetes.

A thousand times today, in offices all over America, hospital patients will be diagnosed with type 2 diabetes. When that happens, a healthcare provider has to make a treatment decision of enormous complexity, often with partial information to go on, and in the span of just a few minutes.

Combination treatment can help improve glucose levels in patients with elevated HbA1Cs.

User-friendly devices help increase use by patients.

Gastric bypass surgery is not only for treating obesity.

GLP1-RA and SGLT2i reduce atherosclerotic major cardiovascular events (MACE) to a similar degree in patients with established ASCVD.

Drug said to be possible fix for multiple primary pathophysiologic abnormalities.

Metformin may help lower the risk of cardiovascular events and death in patients with moderate to severe renal function.

What are the long-term effects of metformin on diabetes prevention?

Metformin and physical activity best prophylactic interventions for prevention.